Phase I Study of Olaparib and Temozolomide in Adult Patients With Recurrent/Metastatic Ewing's Sarcoma or Rhabdomyosarcoma Following Failure of Prior Chemotherapy
Latest Information Update: 20 Feb 2024
At a glance
- Drugs Irinotecan (Primary) ; Olaparib (Primary) ; Temozolomide (Primary)
- Indications Ewing's sarcoma; Rhabdomyosarcoma
- Focus Adverse reactions
- 14 Feb 2024 Planned End Date changed from 1 Jul 2024 to 1 Dec 2024.
- 14 Feb 2024 Planned primary completion date changed from 1 Jul 2022 to 1 Nov 2024.
- 14 Feb 2024 Status changed from recruiting to active, no longer recruiting.